BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics Inc. (BBOT) reported a net loss of $134.0 million for fiscal year 2025, compared to a net loss of $74.3 million in the prior year, reflecting increased investment in its clinical-stage oncology pipeline. The company generated no revenue, as it has no approved products, and incurred total operating expenses of $145.8 million, primarily driven by research and development costs of $121.2 million. Other income of $11.8 million, including $11.3 million in interest income, partially offset operating losses. The company completed a de-SPAC transaction and PIPE financing in August 2025, raising significant capital, resulting in a strong liquidity position with $373.7 million in cash and cash equivalents and total assets of $448.4 million as of December 31, 2025. The accumulated deficit increased to $356.6 million. Forward-looking, BBOT continues to advance three lead product candidates (BBO-8520, BBO-10203, BBO-11818) in Phase 1 trials, with clinical data expected throughout 2026, but expects operating losses to increase as it expands R&D and clinical activities.

Key Takeaways